
               
               
               12 CLINICAL PHARMACOLOGY
               
                  Patients with ESRD retain phosphorus and can develop hyperphosphatemia. High serum phosphorus can precipitate serum calcium resulting in ectopic calcification. Hyperphosphatemia also plays a role in the development of secondary hyperparathyroidism in patients with ESRD.
               
               
               
                  
                     
                     
                     12.1 Mechanism of Action
                     
                        Calcium acetate (ELIPHOSÂ®), when taken with meals, combines with dietary phosphate to form an insoluble calcium phosphate complex, which is excreted in the feces, resulting in decreased serum phosphorus concentration.
                     
                     
                  
               
               
                  
                     
                     
                     12.2 Pharmacodynamics
                     
                        Orally administered calcium acetate from pharmaceutical dosage forms is systemically absorbed up to approximately 40% under fasting conditions and up to approximately 30% under non-fasting conditions. This range represents data from both healthy subjects and renal dialysis patients under various conditions.
                     
                     
                  
               
            
         